HC Wainwright Brokers Lift Earnings Estimates for Zymeworks

Zymeworks Inc. (NASDAQ:ZYME) – Equities research analysts at HC Wainwright lifted their Q3 2026 earnings per share estimates for Zymeworks in a research note issued to investors on Wednesday, August 26th. HC Wainwright analyst R. Burns now anticipates that the company will earn $2.14 per share for the quarter, up from their prior forecast of $2.13. HC Wainwright currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for Zymeworks’ current full-year earnings is $1.25 per share.

Several other research firms have also weighed in on ZYME. Truist Financial upped their price objective on shares of Zymeworks from $31.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zymeworks in a research note on Friday, July 17th. B. Riley Financial restated a “buy” rating and set a $44.00 price target (up from $40.00) on shares of Zymeworks in a report on Monday, August 10th. Deutsche Bank Aktiengesellschaft set a $32.00 price target on shares of Zymeworks in a research note on Wednesday. Finally, Wells Fargo & Company increased their price objective on Zymeworks from $37.00 to $40.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $40.00.

Zymeworks Price Performance

NASDAQ ZYME opened at $29.31 on Thursday. The firm has a market capitalization of $2.08 billion, a price-to-earnings ratio of -14.51 and a beta of 1.15. The company has a 50 day simple moving average of $24.73 and a 200-day simple moving average of $24.77. Zymeworks has a 52-week low of $13.60 and a 52-week high of $30.62.

Zymeworks (NASDAQ:ZYME) last issued its earnings results on Friday, August 7th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.06). Zymeworks had a negative return on equity of 72.30% and a negative net margin of 405.31%.The business had revenue of $3.23 million during the quarter, compared to analyst estimates of $4.54 million. During the same period last year, the business earned $0.03 EPS. The business’s quarterly revenue was down 90.6% on a year-over-year basis.

Zymeworks declared that its Board of Directors has approved a share buyback plan on Thursday, May 14th that authorizes the company to buyback $125.00 million in shares. This buyback authorization authorizes the company to reacquire up to 7% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its shares are undervalued.

Hedge Funds Weigh In On Zymeworks

A number of institutional investors have recently made changes to their positions in the business. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Zymeworks during the second quarter worth $508,000. California State Teachers Retirement System boosted its holdings in Zymeworks by 2,538.8% in the 2nd quarter. California State Teachers Retirement System now owns 986,628 shares of the company’s stock valued at $25,790,000 after purchasing an additional 949,239 shares during the period. Nykredit A S acquired a new stake in Zymeworks in the 2nd quarter worth $25,000. Susquehanna Fundamental Investments LLC acquired a new stake in Zymeworks in the 2nd quarter worth $475,000. Finally, Wellington Management Group LLP bought a new position in shares of Zymeworks during the 2nd quarter worth about $2,876,000. 92.89% of the stock is currently owned by institutional investors.

Key Stories Impacting Zymeworks

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: Jazz’s FDA approval covers Ziihera-based regimens for first-line treatment of adults with unresectable or metastatic HER2-positive GEA, including use regardless of PD-L1 status in certain patients. Phase 3 data showed median overall survival of more than two years, strengthening the commercial outlook for the therapy. Zymeworks FDA approval and milestone announcement
• Positive Sentiment: The approval triggers a $250 million milestone payment from Jazz, bringing total upfront and milestone payments from the partner to $650 million. Zymeworks also remains eligible for up to $1.3 billion in additional Jazz milestones and tiered royalties of 10% to 20% on net sales, plus potential payments and royalties from its BeOne collaboration. Zymeworks gains milestone from Jazz FDA approval
• Positive Sentiment: Analysts raised their valuation estimates: HC Wainwright increased its price target to $55 from $51 and maintained a Buy rating; Citigroup raised its target to $38 from $37 and also maintained Buy. Citizens JMP reaffirmed Market Outperform with a $32 target. Analyst target increases
• Neutral Sentiment: The FDA approval is supported by Phase 3 results, but the confirmatory trial remains ongoing and additional analyses are planned. Continued approval for an earlier biliary tract cancer indication may also depend on confirmatory evidence.
• Negative Sentiment: Zymeworks remains dependent on Jazz and BeOne for development, regulatory execution and commercialization. Delays, weaker-than-expected sales, unsuccessful confirmatory trials or safety concerns could reduce future milestone and royalty income.

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.